We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Super-Resolution Imaging Detects Parkinson's 20 Years Before First Motor Symptoms Appear

By LabMedica International staff writers
Posted on 18 Sep 2024

Parkinson's disease is the second most common neurodegenerative disorder globally, affecting approximately 8. More...

5 million people today. This debilitating condition is characterized by the destruction of dopamine-producing neurons in the brain's Substantia Nigra. Currently, Parkinson's disease is diagnosed primarily based on clinical symptoms such as tremors or gait disturbances, along with associated questionnaires. However, these symptoms typically appear at a relatively advanced stage of the disease, by which time over 50%, and in some cases up to 80%, of the dopaminergic neurons in the Substantia Nigra have already been lost. As a result, available treatments are limited, mainly addressing motor issues.

A key feature of Parkinson's is cell death caused by the accumulation of the alpha-synuclein protein. This protein begins to aggregate approximately 15 years before symptoms appear, and cell death starts 5-10 years before diagnosis is possible using current methods. This leaves a significant diagnostic window of up to 20 years, during which the disease could potentially be detected and prevented before symptoms manifest. If the process is identified early in individuals aged 30, 40, or 50, it may be possible to prevent further protein aggregation and subsequent cell death. Researchers at Tel Aviv University (Tel Aviv, Israel), in collaboration with three major Israeli medical centers, have now developed a novel method for detecting protein aggregation in cells. This technology could allow for diagnosis up to 20 years before the onset of motor symptoms, paving the way for early intervention or prevention of the currently incurable disease.

This new approach utilizes super-resolution microscopy combined with computational analysis to precisely map the molecules and structure of protein aggregates. Previous research has shown that alpha-synuclein aggregates also form in other parts of the body, including the skin and digestive system. In the current study, the researchers examined skin biopsies from 7 people with Parkinson's disease and 7 people without the condition. Using a unique microscope and a technique called super-resolution imaging, combined with advanced computational analysis, the team was able to map the distribution and aggregation of alpha-synuclein molecules. The findings, published in Frontiers in Molecular Neuroscience, revealed a higher concentration of protein aggregates in individuals with Parkinson's compared to those without the disease. Additionally, nerve cell damage was observed in areas with large concentrations of the pathological protein. With this proof of concept, the researchers plan to expand their study by analyzing a larger sample of 90 biopsies—45 from healthy individuals and 45 from those with Parkinson's disease—in order to further explore differences between the two groups.

"Our technology will enable the detection of initial signs of Parkinson's at the cellular level up to 20 years before the first motor symptoms appear. We hope that such early diagnosis will facilitate preventive treatment for this currently incurable disease," the researchers noted.


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Mini Vortex Mixer
Vornado
New
C-Reactive Protein Rapid Test
Afinion CRP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.